Sign In
Buy MLYS
$25.61
+0.240 (+0.95%)
At Close: Jun 23, 2026
Mineralys Therapeutics to Announce First Quarter 2023 Financial Results and Host Conference Call on Monday, May 15, 2023
08:00am, Monday, 01'st May 2023
RADNOR, Pa., May 01, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnor
Strong Small-Cap Insider Buys: Q1 2023
12:15am, Wednesday, 26'th Apr 2023
Strong Small-Cap Insider Buys: Q1 2023.
Mineralys: New IPO And A Leader In The Hypertension Drug Development Space
03:17pm, Friday, 21'st Apr 2023
Mineralys: New IPO And A Leader In The Hypertension Drug Development Space.
Mineralys Therapeutics to Announce Fourth Quarter 2022 Financial Results and Host Conference Call on Wednesday, March 15, 2023
04:05pm, Wednesday, 01'st Mar 2023
RADNOR, Pa., March 01, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abn
There's a Lot to Love About Mineralys' Valentine's Day IPO
09:23am, Monday, 13'th Feb 2023
It has been less than a year since Mineralys Therapeutics (NASDAQ: MLYS) listed its IPO, but the activity has been quite hot, particularly since the top of the year. With 2.71 million in trading volum
Mineralys Therapeutics sets IPO terms, which could value the HPV treatment company at nearly $600 million
08:29am, Thursday, 02'nd Feb 2023
Mineralys Therapeutics Inc. MLYS, has set terms for its initial public offering, in which the Pennsylvania-based hypertension treatment company looks to raise up to $160 million. the company is offeri
Hypertension Drug Maker Mineralys Therapeutics Prepares for $100 million IPO
10:47pm, Thursday, 19'th Jan 2023
A new biopharma play is on its way as hypertension medicine developer Mineralys Therapeutics prepares to come to market.
Mineralys Therapeutics Builds On Phase 2 Trial Success With IPO Filing
10:45pm, Thursday, 19'th Jan 2023
Mineralys Therapeutics has filed to raise drug candidate development funding via a U.S. IPO. The firm is developing treatments for hypertension and chronic kidney disease.
